Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, PD-L1–high advanced non-small cell lung cancer: a randomized, open-label, phase 3 trial
Byoung Chul Cho,Jong Seok Lee,Yi-Long Wu,Irfan Cicin,Manuel Cobo Dols,Myung-Ju Ahn,Kristof Cuppens,Rémi Veillon,Ernest Nadal,Josiane Mourão Dias,Claudio Martin,Martin Reck,Edward B Garon,Enriqueta Felip,Luis Paz-Ares,Francoise Mornex,Everett E Vokes,Alex A Adjei,Clifford Robinson,Masashi Sato,Yulia Vugmeyster,Andreas Machl,Francois Audhuy,Surendra Chaudhary,Fabrice Barlesi,Edward B. Garon,Everett E. Vokes,Alex A. Adjei
DOI: https://doi.org/10.1016/j.jtho.2023.08.018
IF: 20.121
2023-08-20
Journal of Thoracic Oncology
Abstract:Introduction Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII (a TGF-β "trap") fused to a human IgG1 monoclonal antibody blocking PD-L1, has shown clinical activity in a phase 1 expansion cohort of patients with PD-L1–high, advanced non-small cell lung cancer (NSCLC). Methods This adaptive phase 3 trial (NCT03631706) compared the efficacy and safety of bintrafusp alfa versus pembrolizumab as first-line treatment in patients with PD-L1–high advanced NSCLC. Primary endpoints were progression-free survival (PFS) according to RECIST 1.1 per independent review committee (IRC) and overall survival (OS). Results Patients (N=304) were randomized 1:1 to receive either bintrafusp alfa or pembrolizumab (n=152 each). The median follow-up was 14.3 months (95% CI 13.1-16.0 months) for bintrafusp alfa and 14.5 months (95% CI 13.1-15.9 months) for pembrolizumab. PFS by IRC was not significantly different between bintrafusp alfa and pembrolizumab arms (median 7.0 months [95% CI 4.2 months-not reached (NR)] versus 11.1 months [95% CI 8.1 months-NR]; HR=1.232 [95% CI, 0.885-1.714]). Median OS was 21.1 months (95% CI 21.1 months-NR) for bintrafusp alfa and 22.1 months (95% CI: 20.4 months-NR) for pembrolizumab (HR=1.201 [95% CI, 0.796-1.811]). Treatment-related adverse events (TRAEs) were higher with bintrafusp alfa versus pembrolizumab; grade 3/4 TRAEs occurred in 42.4% versus 13.2% of patients, respectively. The study was discontinued at an interim analysis as it was unlikely to meet the primary endpoint. Conclusions First-line treatment with bintrafusp alfa did not demonstrate superior efficacy compared with pembrolizumab in patients with PD-L1–high, advanced NSCLC.
oncology,respiratory system